Trial · NCT07889453
Registered outcomes31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 31
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Body Weight at 12 Months - T2D Switch TZP Cohort | Baseline to follow-up (6-12 months) | Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with T2D who switched from injectable semaglutide to tirzepatide during the index period. |
| Primary | Change from Baseline in Body Weight at 12 Months - Obesity Switch TZP Cohort | Baseline to follow-up (6-12 months) | Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with obesity (non-diabetes) who switched from injectable semaglutide to tirzepatide during the index period. |
| Secondary | Change from Baseline in HbA1c at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in HbA1c among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Percent Body Weight at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in percent body weight (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Body Mass Index (BMI) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in BMI (kg/m\^2) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Blood Pressure at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in blood pressure (mmHg) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Waist Circumference at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in waist circumference (cm) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Estimated Glomerular Filtration Rate (eGFR) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in eGFR (ml/min/1.73m\^2) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Urine Albumin-to-Creatinine Ratio (uACR) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in uACR (mg/mmol) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Alanine Transaminase (ALT) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in ALT (U/L) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Lipids at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in lipids (mmol/L) among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Insulin use (none, basal only, basal-bolus) - T2D Cohort | Baseline to follow-up (6-12 months) | insulin use among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Number of Antihyperglycemic Agents (AHAs) at 12 Months - T2D Cohort | Follow-up (6-12 months) | number of AHAs at 6-12 months follow-up among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Proportion of Individuals who Discontinued Treatment during Follow-up Period (6-12 Months) - T2D Cohort | Baseline to follow-up (6-12 months) | Proportion of individuals who discontinued treatment during follow-up period among individuals living with T2D who switched from injectable semaglutide to tirzepatide and a propensity score-matched group of individuals living with T2D maintaining semaglutide |
| Secondary | Change from Baseline in Percent time in range (TIR) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Percent TIR (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using continuous glucose monitoring (CGM) |
| Secondary | Change from Baseline in Percent Time Above Range (TAR) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in percent TAR (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM |
| Secondary | Change from Baseline in Percent Time Below Range (TBR) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in percent TBR (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM |
| Secondary | Change from Baseline in Percent TBR in Level 2 Hypoglycemia at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in percent TBR level 2 (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM |
| Secondary | Change from Baseline in Percent Time In Tight Range (TITR) at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in percent TITR (%) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM |
| Secondary | Change from Baseline in Mean glucose at 12 Months - T2D Cohort | Baseline to follow-up (6-12 months) | Change in mean glucose (mmol/L) among individuals living with T2D who switched from injectable semaglutide to tirzepatide, using CGM |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07889453/registered